µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º rV
6&: \
V\
1pn7~V
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ pl#2JA8
:%&|5Ytb
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) CjFnE
G5Mo IC
1. ICAM-1 H$D),s
gv
gc<w nm|
2. interleukin 12(IL-12) 'dXGd.V7u
v3p'*81;
3. tumor infiltrating lymphocyte L0lqm0h
k -V3l
4. TCR/CD3 complex LyR bD$m
$U/|+*
5. hematopoietin receptor family b((>?=hh
S4ys)!V1V
6. individual idiotype(IdI) F<V.OFt
cFD3
7. integrin n0a|GZyO]
634OH*6
8. colony-stimulatory factor (CSF) rv?4S`Z,x$
c0ue[tb
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© @sdH
B./
m[}@\y
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? \{EYkk0]
"Snt~:W>
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£
g)mjw
Nsf>b 8O
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠJ?9n4
u
|Vo{ {)
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 0-Ga2Go9
: Tcvj5
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) PcQ\o>0")
HO_!/4hrU
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ yz<$?G
blz
&_$0lIDQ
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) j Gp&P
5wa'SexqE
3. immunoglobulin superfamily (IgSF) -pHUC't
~s{
V!)0
4. selectin d:Oo5t)MN
=D&XE*qkZ
5. anti-idiotypic antibody (¦ÁId) U4NH9-U'
#62*'.B4
6. major histocompatibility complex(MHC) RT.
%\)))
tR\cS)
7. immunotolerance =o:1Rc7J
2YQ;Kh"S
8. biological reponse modifier(BRM) t3b M4+n
" ?Ux\)*
9. immune reponse gene (Ir gene) skYHPwJdW
VXnWY8\
10. reshaped antibody (or reconstituted antibody) NY6;\ 7!n
?3%r:g4
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Pm]lr|Q{I
u2S8DuJ
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ B7wzF"
,A5}H
RW%
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? R=3|(R+kA
KF6N P
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 2Ab`i!#
AyNpY_B0c
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? nvCp-Z$
&;bey4_J
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ `oTV)J'~
Y>T<Qn^D
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? +k
h
Tl:
RG=i74a
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 9{}"tk5$h
*&tTi
v{^
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ k(M"k!M
H|$
*HQm
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? oWx^_wQ-=
J 7sH]
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 3kT?Y7<fv
/x)i}M)
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: l$kO%E'
K%W;-W*'
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: (w#)|9Cxm
G^cMY$?99
̉񧄤 "[rz*[o8I
E,dUO;
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© =7#"}%4Q
0>46ZzxUZ
1. CD8
cml~Oepf
#C'E'g0
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) A^$xE6t
cq 5^7.
3. immunoglobulin fold(Ig fold) 5wdKu,nq
w ~"%&SNN
4. cadherin (Ca-dependent cell adhesion moleculers) BR-wL3x
b
u\MxQIo'u
5. idiotype-anti-idiotypic antibody immune network theory db=S*LUbl
9~$E+m(
6. HLA class II antigen Pd& Npp3
(`_fP.Ogb
7. complementarity-determining region (CDR) Um4D
Vg5
$iMLT8U
8. perforin(or pore-forming protein ,PFP) KX3A|
uL@%M8n
9. high affinity IL-2 receptor
9ZG:2ncdJ
xX9snSGz
10. artificial active immunization ^16
zZ*
3Agyp89}Q
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© -"{g kjuv
mhOgv\?
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ-rjQ^ze
sekei6#fi
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 (+cZP&o
+]zRn
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ -'L~Y~'.
CEBG9[|
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 61_-G#W
,c0LRO
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ v`jHd*&6)
aJtpaW@
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? i7v=o#
_h1eW9q
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 9$U4x|n
6O.kKhk
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ Z
h9D^I
(i1x<
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ = &?&}pVF
HRjbGc|[
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ?G!~&
z}.6yHS
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© a
j$& 9][
tLN^k;w
1. immunoglobulin gene rearrangement &Td)2Wt
:g'
'GqGZ
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) GCiG50Z=
sLJ]N0t
3. flow cytometry(FCM) `?WN*__["
9wGsHf8]
4. carrier effect S
w%6-
mvc ;.
+
5. positive selection of T lymphocytes in thymus =Ry8E2NuM
Zlh 2qq
6. mouse TH1(Th1) and TH2(Th2) subsets _j3rs97@|
%8%|6^,
7. perforin (pore-forming protein ,PFP) x3#:C=
BBGub?(dR
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Im!b-1
!L
q'o?
9. SH-2(src-homology region 2)
-u<F>C
oYA"8ei =
10. Ab2¦Â (internal image) t']/2m.&p
im9EV|;
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© U<=d@knH
Mp!1xx
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ~n) |
|6DJ5VFzD
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? W2h4ej\s
T}1"
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠeq8faC5
<ta{)}IN^
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ n3&h1-
wb(S7OsMO
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠEA1&D^nT
;r~1TUKb
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) lxgfi@@+h
Bhx.q,X
ÃâÒßѧרҵ£º QGV#AID3XW
qzA_ ~=g
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ \o2l;1~
l<4P">M!.
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? /ar0K9`c
Vj1V;dHv
´«È¾²¡Ñ§×¨Òµ£º n{L^W5B
.bP8
Z=
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ YT'V/8US
j7a}<\
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Yy]TU} PY
W.cc!8
Ïû»¯×¨Òµ£º )6X-m9.X
lc~c=17
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ g@s`PBF7`
OvwoU=u
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 6bjZW ~
+]-'{%-zK
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ [N~
-9
!t~tIJ>6
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© kb"Fw:0
"x$L2>9
1. Fas(CD95)/FasL )!E:
cmU0=js.
2. common chain of cytokine receptor qc)+T_m
h`O$L_Z
3 . TCR/CD3 complex B:UPSX)A
#
c1LOz
4. negaive selection of thymocytes iR{@~JN=)
xW9R-J\W
5. artificial active immune \8\TTkVSq
;@gI*i
N"
6. anti-idiotypic aQY.96yo
lH/"47
7. IgSF L7GNcV]c
(vi^ t{k
8. Integrin dQ_'8
)
hR2 R
9. chemokine 2sG1Hox
4, Vx3QFZ
10. B7/CD28 ^!k_"C)B
n!X%i+|4x
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Er$&}9G+-
TPkP5w
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ F2Ny=H&G
'
Gx\
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ |FlB#
a5pM ~.]
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ ~+BU@PHv
|na9I6
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Vi'7m3&
9<P%?Q
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ .Q@]+&`|}i
XPt>klf
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ TI"Ki$jC
p`U#
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© lY,9bSF$
"OkZ
[E)
1. B7/CD28 rXTdhw?+
}
MP_
2. Th1 subset hmb=_W
m)6-D-
&7
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© qf[J-"o
PT&qys2k
4. antibody affinity maturation XIM?$p^
ci 22f
w0
5. AP-1 fG.6S"|M
es+ZPX>Y
6. single chain variable fragment£¨ScFv£© QOJ5
m,w^,)
7. NK cell receptor 7(LB}
5Go@1X]I
8. Zinkernagel-Doherty phenomenon Yc5)
^v
DC$> 5FDv
9. Ig fold $Nj'
_G\}
w>RwEU+w=@
10. CD40/CD40L <<YH4}wZ
poqNiOm4%
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© '^2bC
\C1`F[d_
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ a'my0
m
+~lPf.
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ k>\s6
2)q$HUIX
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Y#U0g|UDn
de"+ABR
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ P2U [PO
0qN?4h)7
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 8)}A}x
XJ7mvLM;
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ k]A$?C0Q<%
:C#(yp
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ RUV:
il:RE8
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© KKw J=za
1tCe#*|95
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© M >s,I^
FWpb5jc)3
1.Co-stimulators (or co-stimulating molecules) nrz2f7d$
'c/Z
W
2.NK-kB I h 19&D
hr GfA
3.Immunoglobulin superfamily 9m2Yrj93
Sh o] ~)XX
4.antigen-presenting cell (APC) R94ID@L
F
roWg~U(S
5.death domain 0BHSeO,
)9$>i5l
6.CCR and CXCR ,*{9
g6
<0^L L
7.Lectin (or mitogen) J[4IO
soB5sFt&]
8.Clusters of differentiation, CD) (n~GKcA
3Qoa?*
9.B7 family vip&
b}u
xrCb29{
10.Cytotoxic T lymphocyte, CTL) "_36W
X
5R"(4a P
11.IL-15 and IL-15 receptor (IL-15R) ugMfpT)
<+${
gu?^
12.MHC restriction jM|-(Es.)
LuUfdzH
13.Affinity-chromatography D= LLm$y
'6W|,
14.Cyctosprin A, CsA q8e34Ly7
m%G:|`f7
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) _^"0"<,
V
sMTzGr
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© zz~AoX7V6
8 ,<F102(
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 f6-OR]R5
HOrD20
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 9H4NvB{
u!WjG@
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ NU?05sF
Fj~,>
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ^u[n!R\
DU>#eR0G
ÃâÒßѧרҵ£º \9}RAr#2]N
/
MUa
b*h
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ U4hFPK<
2PrUI;J$
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ "TboIABp:H
UX& ?^]
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ >SR!*3$5
@3F 4Lg6H|
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) tEXY>=
AvS<b3EoN
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) c0%.GcF0{
"}(g3Iy
1. ADCC(antibody dependent cell-mediated cytotoxicity) 8
qY\T0
H3{FiB]
2. »·æß¾úËØ(cyclosporin) 9n
rH
6]
@!UuK;
3. KIR(killer cell inhibitory receptor) ,XJ
Xw(LM
*Fe
4. HLDA(human leucocyte differentiation antigen) @{|vW
L(bYG0ZI5C
5. Interleukin 18(IL-18) Qg\{d)X[N
6pHn%yE*
6. ÕûºÏËØ(integrin) u\9t+wi}<
`?f Y!5BA
7. Fas/FasL 5A~lu4-q
-t:~d:
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) eiJ13`T
X?'v FC
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) xElHYh(\
!BocF<U E
10. Th1/Th2 <ETR6r
{O4y Y=G
11. »ùÒòÒßÃç(DNAÒßÃç) U;l!.mze
M:4N'#`
12. chemokines and chemokine receptor 9HjtWQn
>#
{,(8\
13. ÃâÒßÄÍÊÜ }5 2]
Y]ZNAR
14. ¹²´Ì¼¤·Ö×Ó ]W-7 U_
)9.i'{{ 0
15. ËÀÍö½á¹¹Óò(death domain) m3cO{
1I
phT|w
H
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) OqaVp/,
&rcC7v K9
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? o
IUjd
Zi0B$3iOb
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠGuc~]
B
ymIjm0jVh
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î eC9nOwp]xH
8op,;Z7Y
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ HW{si]~q
L=7U#Q/DE
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå lcv&/ A
$6(,/}==0
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ MQ9Nn|4
;Y&<psQeb
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) $*%ipD}f
"|2|Vju%
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ * 5H
bVB_KE
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ )9^0Qk' ]
'^TQ Ubw
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£